Skip to main content
OpenTrials

Clinical trial condition

Urothelial Carcinoma

Explore clinical trials studying Urothelial Carcinoma. Study availability and eligibility vary by location and protocol.

239 public trials 74 recruiting studies
Refine in advanced search Browse all conditions

Urothelial Carcinoma trial results

Active, Not Recruiting

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

NCT06111235

Conditions
Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +17 more
Locations
  • Urology Centers of Alabama PC Homewood, Alabama, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Mayo Clinic Scottsdale, Arizona, United States
  • Arizona Institute of Urology PLLC Tucson, Arizona, United States
View all 95 locations
View Trial Details
Active, Not Recruiting

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

NCT03967977

Conditions
Carcinoma, Carcinoma, Transitional Cell, Neoplasms, +3 more
Locations
  • Anhui Provincial Hospital Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Peking University First Hospital Beijing, Beijing Municipality, China
  • Beijing Friendship Hospital, Capital Medical University Beijing, Beijing Municipality, China
View all 46 locations
View Trial Details
Active, Not Recruiting

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

NCT01366144

Conditions
Adnexal Diseases, Breast Carcinoma, Breast Diseases, +70 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 17 locations
View Trial Details
Active, Not Recruiting

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

NCT02717156

Conditions
Carcinoma, Carcinoma, Transitional Cell, Genital Diseases, +14 more
Locations
  • City of Hope Duarte, California, United States
  • LAC+USC Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • USC Norris Oncology/Hematology - Newport Beach Newport Beach, California, United States
View Trial Details
Active, Not Recruiting

JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study

NCT06412848

Conditions
Carcinoma, Carcinoma, Transitional Cell, Neoplasms, +3 more
Locations
  • Hirosaki University Hospital Hirosaki, Aomori, Japan
  • Ehime University Hospital Tōon, Ehime, Japan
  • Kurume University Hospital Kurume, Fukuoka, Japan
  • Hokkaido University Hospital Sapporo, Hokkaido, Japan
View all 26 locations
View Trial Details
Active, Not Recruiting

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

NCT04152499

Conditions
Adnexal Diseases, Breast Cancer, Breast Diseases, +48 more
Locations
  • Los Angeles Hematology Oncology Medical Group Glendale, California, United States
  • University of California Los Angeles Los Angeles, California, United States
  • Florida Cancer Specialists and Research Institute Sarasota, Florida, United States
  • START MidWest Grand Rapids, Michigan, United States
View all 109 locations
View Trial Details
Active, Not Recruiting

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT05243550

Conditions
Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +16 more
Locations
  • Arizona Urology Specialists Tucson, Arizona, United States
  • Loma Linda University Medical Center Loma Linda, California, United States
  • Genesis Research San Diego, California, United States
  • Wichita Urology Group Wichita, Kansas, United States
View all 65 locations
View Trial Details
Active, Not Recruiting

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

NCT05661955

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +26 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Fujian Cancer Hospital Fuzhou, Fujian, China
  • The Second Hospital and Clinical Medical School, Lanzhou University Lanzhou, Gansu, China
  • Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong, China
View all 18 locations
View Trial Details

Related conditions